Impact of Brokerage Rating on Biogen Inc.(BIIB)

Many Biogen Inc.(BIIB) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Biogen Inc was Upgraded by Citigroup to Buy on Feb 7, 2017. Company shares were Reiterated by Raymond James on Dec 29, 2016 to Strong Buy, Raises Price Target to $ 386 from a previous price target of $375 .Company shares were Reiterated by Stifel on Dec 9, 2016 to Hold, Raises Price Target to $ 298 from a previous price target of $291 .

Biogen Inc Last issued its quarterly earnings results on Jan 26, 2017. The company reported $5.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.08. Analyst had a consensus of $4.96. The company had revenue of $2872.00 million for the quarter, compared to analysts expectations of $2939.36 million. The companys revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.50 EPS.

Biogen Inc. (NASDAQ:BIIB) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.66 by 16 Brokerage Firm. 10 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 5 Brokerage Firms have advised hold.

Biogen Inc. (NASDAQ:BIIB): 15 Analyst have given the stock of Biogen Inc. (NASDAQ:BIIB) a near short term price target of $324.87. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $34.66. The higher price target estimate is at $380 while the lower price estimates are fixed at $265.

Biogen Inc. (NASDAQ:BIIB) rose 2.23% or 6.23 points on Tuesday and made its way into the gainers of the day. After trading began at $279.86 the stock was seen hitting $286.06 as a peak level and $279.01 as the lowest level. The stock ended up at $285.14. The daily volume was measured at 2,404,545 shares. The 52-week high of the share price is $307.32543 and the 52-week low is $205.42501. The company has a market cap of $61,577 million.

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimers disease, lupus nephritis to neuropathic pain.